Sort   by:  
 Page size 
UnknownPre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Not available
S-EPMC4700047 | biostudies-literature
UnknownContinuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Not available
S-EPMC7217157 | biostudies-literature
UnknownLong-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Not available
S-EPMC12492902 | biostudies-literature
UnknownRisk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
Not available
S-EPMC5902836 | biostudies-literature
UnknownEfficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Not available
S-EPMC4643643 | biostudies-literature
UnknownPerinatal and 2-year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 randomised trial protocol.
Not available
S-EPMC9014041 | biostudies-literature
UnknownVaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.
Not available
S-EPMC9124924 | biostudies-literature
UnknownSARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.
Not available
S-EPMC9991062 | biostudies-literature
UnknownOutcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Not available
S-EPMC9162476 | biostudies-literature
UnknownAn international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Not available
S-EPMC8811537 | biostudies-literature
Sort   by:  
 Page size